Low Level Laser Therapy Reduces the Development of Lung Inflammation Induced by Formaldehyde Exposure

Cristiane Miranda da Silva, Mayara Peres Leal, Robson Alexandre Brochetti, Tárcio Braga, Luana Beatriz Vitoretti, Niels Olsen Saraiva Câmara, Amílcar Sabino Damazo, Ana Paula Ligeiro-de-Oliveira, Maria Cristina Chavantes, Adriana Lino-Dos-Santos-Franco, Cristiane Miranda da Silva, Mayara Peres Leal, Robson Alexandre Brochetti, Tárcio Braga, Luana Beatriz Vitoretti, Niels Olsen Saraiva Câmara, Amílcar Sabino Damazo, Ana Paula Ligeiro-de-Oliveira, Maria Cristina Chavantes, Adriana Lino-Dos-Santos-Franco

Abstract

Lung diseases constitute an important public health problem and its growing level of concern has led to efforts for the development of new therapies, particularly for the control of lung inflammation. Low Level Laser Therapy (LLLT) has been highlighted as a non-invasive therapy with few side effects, but its mechanisms need to be better understood and explored. Considering that pollution causes several harmful effects on human health, including lung inflammation, in this study, we have used formaldehyde (FA), an environmental and occupational pollutant, for the induction of neutrophilic lung inflammation. Our objective was to investigate the local and systemic effects of LLLT after FA exposure. Male Wistar rats were exposed to FA (1%) or vehicle (distillated water) during 3 consecutive days and treated or not with LLLT (1 and 5 hours after each FA exposure). Non-manipulated rats were used as control. 24 h after the last FA exposure, we analyzed the local and systemic effects of LLLT. The treatment with LLLT reduced the development of neutrophilic lung inflammation induced by FA, as observed by the reduced number of leukocytes, mast cells degranulated, and a decreased myeloperoxidase activity in the lung. Moreover, LLLT also reduced the microvascular lung permeability in the parenchyma and the intrapulmonary bronchi. Alterations on the profile of inflammatory cytokines were evidenced by the reduced levels of IL-6 and TNF-α and the elevated levels of IL-10 in the lung. Together, our results showed that LLLT abolishes FA-induced neutrophilic lung inflammation by a reduction of the inflammatory cytokines and mast cell degranulation. This study may provide important information about the mechanisms of LLLT in lung inflammation induced by a pollutant.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Treatment with LLLT reduces cell…
Fig 1. Treatment with LLLT reduces cell recruitment in the blood (A) but did not alter the number of cells in the bone marrow after FA exposure.
Group of rats was exposed or not to FA inhalation (1%, 90 min/day, 3 days) and treated or not with LLLT (30mW, 1,8 J, 60s/point, total 540s, 1 and 5h post each FA inhalation). Non-manipulated rats were used to obtain basal parameters. The number of cells in the blood (panel A) and in the bone marrow (Panel B) was determined 24 h after the last FA inhalation. Data mean ± SD of 6 animals per group. *PθP<0.05 in relation to FA group.
Fig 2. Treatment with LLLT reduces neutrophilic…
Fig 2. Treatment with LLLT reduces neutrophilic lung inflammation after FA exposure.
Group of rats was exposed or not to FA inhalation (1%, 90 min/day, 3 days) and treated or not with LLLT (30mW, 1.8 J, 60s/point, total 540s, 1 and 5h post each FA inhalation). Non-manipulated rats were used to obtain basal parameters. The number of cells in the bronchoalveolar lavage (BAL) (panel A) and myeloperoxidase activity in the lung tissue (MPO) (Panel B) were determined 24 h after the last FA inhalation. Data mean ± SD of 6 animals per group. *PθP<0.05 in relation to FA group.
Fig 3. Treatment with LLLT reduces lung…
Fig 3. Treatment with LLLT reduces lung vascular permeability after FA exposure.
Group of rats was exposed or not to FA inhalation (1%, 90 min/day, 3 days) and treated or not with LLLT (30mW, 1.8 J, 60s/point, total 540s, 1 and 5h post each FA inhalation). Non-manipulated rats were used to obtain basal parameters. The lung vascular permeability in the parenchyma (A), trachea (B) and intrapulmonary bronchi (C) was assessed immediately after the last FA inhalation. Data are mean ± SD of 6 animals per group. *PθP<0.05 in relation to FA group.
Fig 4. Treatment with LLLT reduces TNF-alpha…
Fig 4. Treatment with LLLT reduces TNF-alpha and IL-6 while increases IL-10 levels in the BAL fluid after FA exposure.
Group of rats was exposed or not to FA inhalation (1%, 90 min/day, 3 days) and treated or not with LLLT (30mW, 1.8 J, 60s/point, total 540s, 1 and 5h post each FA inhalation). Non-manipulated rats were used to obtain basal parameters. The evaluation of inflammatory cytokines TNF-alpha (A) and IL-6 (B) as well as anti-inflammatory IL-10 (C) in the supernatant of BAL fluid were determined 24 h after the last FA exposure. Data are mean ± SD of 6 animals per group. *PθP<0.05 in relation to FA group.
Fig 5. Treatment with LLLT increases IL-10…
Fig 5. Treatment with LLLT increases IL-10 gene expression and did not alter IL-6 gene expression in the lung tissue after FA exposure.
Group of rats was exposed or not to FA inhalation (1%, 90 min/day, 3 days) and treated or not with LLLT (30mW, 1.8 J, 60s/point, total 540s, 1 and 5h post each FA inhalation). Non-manipulated rats were used to obtain basal parameters. The evaluation of gene expression of inflammatory cytokine IL-6 (A) and anti-inflammatory IL-10 (B) in the lung were determined 24 h after the last FA exposure. Data are mean ± SD of 6 animals per group. *PθP<0.05 in relation to FA group (Panel B).
Fig 6. Treatment with LLLT reduces leukocytes…
Fig 6. Treatment with LLLT reduces leukocytes infiltration and mast cell degranulation in the lung tissue after FA exposure.
The airway inflammation induced by FA inhalation caused an intense cellular infiltration in the perivascular and peribrochiolar and mast cell activation in the lung parenchyma and pleura (arrows) (Panels C and D), whereas in the basal group, only resident leukocytes were observed and the mast cells were intact (arrowhead) (Panels A and B). Although, after the LLLT treatment, both cellular infiltration and mast cell activation were significantly reduced (Panels E and F).

References

    1. Landyshev Iu.S.; Avdeeva N.V.; Goborov N.D.; Krasavina N.P.; Tikhonova G.A.; Tkacheva S.I. 2002. Efficacy of low intensity laser irradiation and sodium nedocromil in the complex treatment of patients with bronchial asthma. Ter Arkh, 74 (3): 25–28.
    1. Faradzheva N.A. 2007. Efficiency of a combination of haloaerosols and helium-neon laser in the multimodality treatment of patients with bronchial asthma. Prob. Tuberk Bolezn Legk, 8: 50–53.
    1. Kashanskaia E.P. and Fedorov A.A. 2009. Low-intensity laser radiation in the combined treatment of patients with chronic obstructive bronchitis. Vopr Kurortol Fizioter Lech Fiz Kult, 2:19–22.
    1. de Lima F.M.; Moreira L.M.; Villaverde A.B.; Albertini R.; Castro-Faria-Neto H.C.; Aimbire F. 2011. Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome. Lasers Med Sci., 26(3):389–400. 10.1007/s10103-010-0874-x
    1. Oliveira M.C. Jr.; Greiffo F.R.; Rigonato-Oliveira N.C.; Custódio R.W.; Silva V.R.; Damaceno-Rodrigues N.R et al., 2014. Low level laser therapy reduces acute lung inflammation in a model of pulmonary and extrapulmonary LPS-induced ARDS, J Photochem Photobiol B., 5(134):57–63.
    1. Aimbire F, Lopes-Martins RA, Castro-Faria-Neto HC, Albertini R, Chavantes MC, Pacheco MT et al.,2006Low-level laser therapy can reduce lipopolysaccharide-induced contractile force dysfunction and TNF-alpha levels in rat diaphragm muscle. Lasers Med Sci.,21(4):238–44.
    1. Silva VR, Marcondes P, Silva M, Villaverde AB, Castro-Faria-Neto HC, Vieira RP, et al. 2014. Low-level laser therapy inhibits bronchoconstriction, Th2 inflammation and airway remodeling in allergic asthma. Respir Physiol Neurobiol.; 194:37–48. 10.1016/j.resp.2014.01.008
    1. Tillie-Leblond I, Gosset P, Tonnel AB.2005. Inflammatory events in severe acute asthma. Allergy,60(1):23–9.
    1. Gülec M., Songur A., Sahin S., Ozen OA., Sarsilmaz M., Akyo O. 2006. Antioxidant enzyme activities and lipid peroxidation products in heart tissue of subacute and subchronic formaldehyde-exposed rats: a preliminary study. Toxicol. Ind. Health, 22 (3):117–124.
    1. Sagai M, Tin Win-Shwe T. 2015Oxidative Stress Derived from Airborne Fine and Ultrafine Particles and the Effects on Brain-Nervous System: Part 2. Nihon Eiseigaku Zasshi.,70(3):220–9. 10.1265/jjh.70.220
    1. Lino dos Santos Franco, A., Damazo A.S., Beraldo de Souza H.R., Domingos H.V., Oliveirafilho R.M., Oliani S.M. et al., 2006. Pulmonary neutrophil recruitment and bronchial reactivity in formaldehyde-exposed rats aremodulated by mast cells and differentially by neuropeptides and nitric oxide. Toxicol. Appl.Pharmacol. 1;214 (1), 35–42.
    1. Lino-dos-Santos-Franco A, Correa-Costa M, Durão AC, de Oliveira AP, Breithaupt-Faloppa AC, Bertoni Jde A, Oliveira-Filho RM, Câmara NO, Marcourakis T, Tavares-de-Lima W. 2011. Formaldehyde induces lung inflammation by an oxidant and antioxidant enzymes mediated mechanism in the lung tissue. Toxicol Lett.; 207(3):278–85. 10.1016/j.toxlet.2011.09.026
    1. Carlson R.M., Smith M.C. Nedorost S.T. 2004. Diagnosis and treatment of dermatitis due to formaldehyde resins in clothing. Dermatitis, 15, 169–175.
    1. Salthammer T. 2013. Formaldehyde in the ambient atmosphere: From an indoor pollutant to an outdoor pollutant? Angew. Chem. Int. Ed. Engl., 52, 3320–3327. 10.1002/anie.201205984
    1. Lino-dos-Santos-Franco A, Domingos HV, de Oliveira AP, Breithaupt-Faloppa AC, Peron JP, Bolonheis S, Muscará MN, Oliveira-Filho RM, Vargaftig BB, Tavares-de-Lima W. 2010. Differential effects of formaldehyde exposure on the cell influx and vascular permeability in a rat model of allergic lung inflammation. Toxicol Lett.; 197(3):211–8.
    1. Lino-dos-Santos-Franco A, Gimenes-Júnior JA, Ligeiro-de-Oliveira AP, Breithaupt-Faloppa AC, Acceturi BG, Vitoretti LB, Machado ID et al., 2013. Formaldehyde inhalation reduces respiratory mechanics in a rat model with allergic lung inflammation by altering the nitric oxide/cyclooxygenase-derived products relationship. Food Chem Toxicol.,59:731–8. 10.1016/j.fct.2013.07.027
    1. Peron JP, de Brito AA, Pelatti M, Brandão WN, Vitoretti LB, Greiffo FR et al., 2015. Human Tubal-Derived Mesenchymal Stromal Cells Associated with Low Level Laser Therapy Significantly Reduces Cigarette Smoke-Induced COPD in C57BL/6 mice. PLoS One;10(8):e0136942 10.1371/journal.pone.0136942
    1. Avci P; Gupta A; Sadasivam MTech, Vecchio D; Pam Z; Pam N et al., 2013. Low-Level Laser (Light) Therapy (LLLT) in Skin: Stimulating, Healing, Restoring. Semin. Cutan. Med. Surg. 32:41–52.
    1. Joensen J; Øvsthus K; Reed RK; Hummelsund S; Iversen VV; Brandao Lopes-Martins, RA et al. 2012. Skin Penetration Time-Profiles for Continuous 810 nm and Superpulsed 904 nm Lasers in a Rat Model. Photomedicine and Laser Surgery 30(12): 688–694. 10.1089/pho.2012.3306
    1. Aimbire F, Albertine R, de Magalhães RG, Lopes-Martins RA, Castro-Faria-Neto HC, Zângaro RA, et al. 2005. Effect of LLLT Ga-As-Al (685 nm) on LPS-induced inflammation of the airway and lung in rat. Lasers. Med. Sci. 20(1), 11–20.
    1. Chavantes M.C. 2005. Pilot study: New treatment applying LLLT in tracheal stenosis, using biomodulated effect. In: WALT, 2005, Guaruja, SP. Photomedicine & Laser Surgery, 1:113.
    1. Tomimura S., Bianca Passos Assumpção Silva, Iris Callado Sanches, Marina Canal, Fernanda Consolim-Colombo, Felipe Fernandes Conti et al., 2014. Hemodynamic Effect of Laser Therapy in Spontaneously Hypertensive Rats. Arq. Bras. Cardiol.,103(2):161–164.
    1. de Lima FM, Aimbire F, Miranda H, Vieira R de P, de Oliveira AP, Albertini R. 2014. Low-level laser therapy attenuates the myeloperoxidase activity and inflammatory mediator generation in lung inflammation induced by gut ischemia and reperfusion: a dose-response study. J Lasers Med Sci.; 5(2):63–70.
    1. Stark MA1, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. 2005. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity, 22(3):285–294.
    1. Eash KJ, Means JM, White DW, Link DC. 2009. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood, 113(19):4711–4719. 10.1182/blood-2008-09-177287
    1. Borregard N. 2010. Neutrophils from marrow to microbes. Immunity, 33: 657–670. 10.1016/j.immuni.2010.11.011
    1. Fialkow L, Wang Y, Downey GP.2007Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med., 15;42(2):153–64.
    1. Garret, M. H.; Hooper, M. A.; Hooper, B. M. 1996.Low levels of formaldehyde in residential homes and a correlation with asthma and allergy in children. Proceedings of the 7 Th International Conference on Indoor Air Quality and Climate: Indoor Air,96(1):617–622, 1996.
    1. Norbäck D, Björnsson E, Janson C, Widström J, Boman G.1995Asthmatic symptoms and volatile organic compounds, formaldehyde, and carbon dioxide in dwellings.Occup Environ Med.,52(6):388–95.
    1. Fujimak H.; Kawagoe A.; Bissonnette E.; Befus D. 1992. Mast cell response to formaldehyde. Int. Arch. Allergy, 98: 324–338.
    1. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M., 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749–786.
    1. Wang YH, Voo SK, Liu B, Chen CY, Uygunglil B, Spoede W, Bernsetin JA, Huston DP, Liu Y. 2010. A novel subset of CD4 Th2 memory/effector cells that produce inflammatory IL-17 cytokine and promote exacerbation of chronic allergic asthma. J. Exp. Med: 207 (11):2479–91. 10.1084/jem.20101376
    1. Wu JY, Chen CH, Wang CZ, Ho ML, Yeh ML, Wang YH. 2013. Low-Power Laser Irradiation Suppresses Inflammatory Response of Human Adipose-Derived Stem Cells by Modulating Intracellular Cyclic AMP Level and NF-KB Activity. PLoS One, 8(1):1–9.
    1. Ostronosova NS.2006[Outpatient use of laser therapy in bronchial asthma]. Ter Arkh,78(3):41–4.

Source: PubMed

3
Abonnere